Evolution of drugs that preserve renal function

Journal of Clinical Pharmacology

Volumn 40, Issue 9, 2000, Pages 978-989

  Basta, E ^a   Bakris, G L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; CLONIDINE; GANGLION BLOCKING AGENT; GUANETHIDINE; HEXAMETHONIUM; HYDRALAZINE; METHYLDOPA; MINOXIDIL; PHENOXYBENZAMINE; PHENTOLAMINE; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; PROPRANOLOL; RAUWOLFIA ALKALOID; RESERPINE; SPIRONOLACTONE; TETRAMETHYLAMMONIUM; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL; VERATRUM ALKALOID;

CARDIOVASCULAR RISK; CLINICAL PHARMACOLOGY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; HISTORY OF MEDICINE; HUMAN; KIDNEY DISEASE; NONHUMAN; PROTEINURIA; RENOVASCULAR HYPERTENSION; REVIEW; TREATMENT OUTCOME;

EID: 0033663154     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009701     Document Type: Review

References (123)

1. Studies on experimental hypertension: Production of persistent elevation of systolic blood pressure by means of renal ischemia
2. On the nature of the pressor action of renin
3. A specific sympathemimtic ergone in adrenergic nerve fibers and its relation to adrenalin and noradrenalin
4. Autonomic nervous system and benign essential hypertension in man: 1. Usual blood pressure, catecholamines, renin and their interrelationships
5. Mechanisms controlling arterial pressure
6. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
7. Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial
8. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
9. Role of dietary protein and blood pressure in the progression of renal disease
10. Calcium channel or beta blockade on progression of diabetic renal disease in African-Americans
11. Joint National Committee report on the diagnosis and treatment of hypertension (JNC VI)
12. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension: Guidelines subcommittee
13. Treatment of hypertension in adults with diabetes to preserve renal function: A consensus approach endorsed by the Scientific Advisory Board of the National Kidney Foundation
14. Circulatory effects of sympathomimetic amines
15. A study of the adrenotropic receptor
16. The pharmacology of adrenergic blockade
17. Antihypertensive agents and the drug therapy of hypertension
18. Antihypertensive agents and drug therapy in hypertension
19. Pharmacology of antihypertensive drugs
20. The methonium compounds
21. The hemodynamic effects of hypotensive drugs in man: III. Hexmethonium
22. A comparison of cardiovascular effects of sodium nitroprusside and trimethaphan
23. Current concepts in treatment of hypertensive emergencies
24. Preganglionic sympathetic activity in normal and in reserpine treated cats
25. Cardiovascular and renal hemodynamic response to reserpine and clinical results of using this agent for treatment of hypertension
26. Inhibition of adrenergic function in the treatment of hypertension
27. Double-blind control study on the comparative effectiveness of reseipine, reserpine and hydralazine and three ganglionic blocking agents, chlorisondamine, mecamylamune and pentolinium tartrate
28. Effects of treatment in morbidity in hypertension: Results in patients with diastolic blood pressure averaging 115 through 120 mm Hg
29. Effects of treatment in morbidity in hypertension II. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg
30. Pathophysiologic assessment of hypertensive heart disease with echocardiology
31. Disparate effects of methyldopa and clonidine on cardiac mass and hemodynamics in rats
32. Effect of methyldopa, clonidine and hydralazine on cardiac mass and hemodynamics in Wistar Kyoto and spontaneously hypertensive rats
33. Regression of left ventricular hypertrophy in two-kidney, one-clip Goldblatt hypertension
34. Hypertensive heart disease
35. Pharmacology of [2(octahydro-l-azocinyl)-ethyl]-guanidine sulfate (SU 5864)
36. Adrenergic neuron blocking agents
37. Guanethidine and related adrenergic neurnal blocking agents
38. Relationships between the release and tissue depletion of norepinephrine from the heart by guanethidine and reserpine
39. Analysis of the acute circulatory effects of guanethidine and bretylium
40. Circulatory effects of guanethidine clinical, renal and cardiac responses to treatment with a novel antihypertensive drug
41. Plasma volume expansion resulting from interference with adrenergic function in normal man
42. Dependence of arterial pressure on intravascular volume in treated hypertensive patients
43. Sympathetic nervous system and hypertension. Therapeutic perspectives
44. Prazosin
45. Effects of prazosin in patients with hypertension
46. Pheochromocytoma
47. Alpha-adrenergic receptor blockade with prazosin
48. Implications of discontinuation of doxazosin arm of ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
49. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria: A randomized crossover study
50. Doxazosin prevents proteinuria and glomerular loss of heparin sulfate in diabetic rats
51. Centrally mediated decrease in sympathetic tone induced by 2-(2,6-dichlorophenylamine) - 2-Imidazoline (ST 155, Catapressan)
52. Clonidine: A new antihypertensive agent
53. The central action of clonidine and its antagonism
54. Reduction of the hypotensive effect of clonidine and alpha methyldopa by various psychotropic drugs
55. Effect of clonidine therapy on renal hemodynamics in renal transplant hypertension
56. Treatment of arterial hypertension in diabetic man: Importance of therapeutic selection
57. Decarboxylase inhibition and blood pressure reduction by alpha methyl-3,4, dihydroxy DL-phenylmine
58. False adrenergic transmitters
59. Central hypotensive effect alpha-methyldopa
60. Effect of methyldopa on plasma renin activity in man
61. Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradranaline
62. The acute hemodynamic effects of alpha-methyldopa
63. Hemodynamic effects of methyldopa (Aldomet) at rest and during exercise in patients with arterial hypertension
64. The effects of alpha-methyldopa on renal function in hypertensive patients
65. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol
66. The use of propranolol in the treatment of hypertension
67. Renal function in patients with essential hypertension receiving nadolol
68. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension
69. Pindolol: A new beta-adrenoreceptor antagonist with partial agonist activity
70. Metoprolol: A review of its pharmacological properties and therapeutic efficacy in hypertension
71. Propranolol inhibition and renin secretion: A specific approach to diagnosis and treatment of renin dependent hypertensive disease
72. Central nervous system effects of four adrenergic blocking agents
73. The renal, forearm and hormonal responses to standing in the presence and absence of propranolol
74. Hemodynamic effects of labetalol and alpha and beta-adrenergic blocking agents in hypertensive subjects
75. Carvedilol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy
76. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies
77. Effects of long-term carvedilol therapy on renal function in essential hypertension
78. New therapeutic approaches to achieve the desired blood pressure goal
79. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminruia: A multiple-center, randomized, open label, controlled study versus atenolol
80. Hypertension and atherosclerosis in primitive and acculturating societies
81. Salt volume and prevention of hypertension
82. Diuretics in hypertension
83. Diuretics as antihypertensive drugs
84. Comparison of captopril and hydrochbrothiazide alone and in combination in mdd to moderate essential hypertension
85. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
86. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: Racial and treatment effects
87. A dipeptidyl carboxypeptidase that converts angiotensin I and reactivates bradykinin
88. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents
89. Angiotensin-converting enzyme inhibition in patients with congestive heart failure
90. Converting enzyme inhibitors in the treatment of hypertension
91. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
92. Therapeutic efficacy of different anti-hypertensive agents on proteinuria and renal function
93. Angiotensin converting enzyme inhibitors: Present and future
94. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
95. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy
96. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy
97. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria
98. Rationale for the chemical development of angiotensin II receptor antagonists
99. Blockade of the renin-angiotensin system
100. Randomised trial of losartan versus captopril in patients over 65 with heart failure
101. Losartan Heart Failure Survival Study-ELITE II
102. Clinical efficacy and safety profiles of AT1 receptor antagonists
103. Calcium channel blockers: Are they created equal with regard to slowing progression of diabetic nephropathy?
104. Preservation of renal function: The spectrum of effects by calcium channel blockers
105. Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers
106. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists
107. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies
108. Some pharmacodynamic effects of 1-hydrazinophthaLazine (C-5968) with particular reference to renal function and cardiovascular response
109. Effect of hypotension-producing drugs in the renal circulation
110. Hydralizine and plasma renin activity
111. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockage
112. Cardiovascular and renal responses to the combination of hexamethonium and 1-hydrazinophthalazine (Apresoline) in hypertensive subjects
113. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockage
114. Vasodilatory drugs in the treatment of hypertension
115. Studies in the control of hypertension by hydralazine: II. Toxic reactions and side effects
116. Minoxidil: An alternative to nephrectomy for refractory hypertension
117. Long-term treatment of severe hypertension with minoxidil, propranolol and furasemide
118. Minoxidil induced hypertrichosis: Treatment with calcium thiologycolate depilatory
119. Treatment of severe hypertension with minoxidil: Advantages and limitations
120. Minoxidil induced systemic lupus erythematous
121. Vasopeptidase inhibition: A new concept in blood pressure management